Annual Revenue Comparison: Bio-Techne Corporation vs Xencor, Inc.

A Decade of Growth: Bio-Techne Corporation vs. Xencor, Inc.

In the ever-evolving biotech industry, revenue growth is a key indicator of success. Over the past decade, Bio-Techne Corporation has consistently outperformed Xencor, Inc., showcasing a robust upward trajectory. Starting in 2014, Bio-Techne's revenue was approximately 38 times that of Xencor. By 2023, Bio-Techne's revenue had surged by over 200%, reaching a peak of $1.14 billion, while Xencor's revenue increased by nearly 1,700% but still lagged behind at $168 million.

This comparison highlights Bio-Techne's strategic advancements and market positioning, which have enabled it to maintain a competitive edge. Meanwhile, Xencor's impressive growth rate, despite its smaller base, signals potential for future expansion. As we look to 2024, the absence of data for Xencor suggests a need for further analysis to understand its trajectory. This revenue comparison underscores the dynamic nature of the biotech sector and the varying strategies companies employ to achieve growth.